Abstract:Background: In patients with Metabolic associated fatty liver disease (MAFLD), hepatic steatosis is an independent predictor for insulin resistance and cardiovascular risk and hence mortality. Urine biomarker is less complex and has a relatively lower dynamic range with less technical challenges compared to blood. However, little was known whether the urine sample could reflect the altered metabolic/lipid feature in liver and the severity of hepatic steatosis. Therefore, the aim of present study was to investigate the urine molecular pattern and to verify new urine biomarker for hepatic steatosis in MAFLD patients. Method: Hepatic steatosis was measured by Magnetic resonance imaging (MRI) that measure the proton density fat fraction (MRI-PDFF). Mild hepatic steatosis defined as MRI-PDFF 5-10% and the severe hepatic steatosis was defined as MRI-PDFF>10%. Urine samples of 7 healthy controls, 8 MAFLD patients with mild hepatic steatosis, and 12 MAFLD patient with severe steatosis were collected. Proteomic measurements of urine samples were done by mass spectrometry. Western blot and Elisa were performed for validation of potential urine biomarker. Results: There were 53 proteins identified with significantly different expressions among the healthy control, mild steatosis and severe steatosis in MAFLD patients by proteomic data. GO and KEGG analysis of these significantly changed urinary molecular features implied that the MAFLD could result in the dysregulation of carbohydrate derivative catabolic process, glycosaminoglycan process, aminoglycan metabolic process, catabolic process, inflammatory response, insulin-like growth factor receptor, GTPase complex, PI3K−Akt signaling pathway and cholesterol metabolism. Nextly, Alpha-1-acid glycoprotein 1 (ORM1) and ceruloplasmin were the most correlated with clinical parameters in MAFLD, including liver fat content, fibrosis, ALT, triglyceride, glucose, HOMA-IR, and C-reactive protein. Finally, the validation of urine sample (30 cases) by Elisa showed that both ceruloplasmin (healthy control 3.02 ± 1.43 vs. mild steatosis 4.27 ± 1.18 vs. severe steatosis 5.61 ± 1.31, p<0.001) and ORM1 (1.19 ± 1.085 vs. 3.41 ± 2.61 vs. 4.68 ± 3.154, p=0.011) showed an increased tendency from healthy control to mild steatosis and severe steatosis, those results were further validated by western blot. Conclusion: Proteomics profiling allowed us to reveal molecular patterns accompanying hepatic steatosis in MAFLD. Urine ORM1 and ceruloplasmin are potential biomarkers for population-based screening, diagnosing and follow-up for mild/severe hepatic steatosis. Funding Information: This study was supported by the Post-Doctor Research Project of West China Hospital of Sichuan University (grant numbers 2020HXBH079) and National Natural Science Foundation of China (grant numbers 81900512). Declaration of Interests: The authors declare that there are no competing interests associated with the manuscript. Ethics Approval Statement: The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The Institutional Review Board Committee of West China Hospital of Sichuan university approved the study protocol. The study was performed by following the ethical guidelines expressed in the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. Informed consent was obtained from all subjects.

Preliminary study of the urinary proteome in Li and Han ethnic individuals from Hainan

Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes

Analysis of Urinary Proteomic Patterns for Diabetic Nephropathy by ProteinChip.

Itraq-Based Comparative Proteomics Analysis Reveals Specific Urinary Biomarkers for Various Kidney Diseases.

Proteomic Analysis of Individual Variation in Normal Livers of Human Beings Using Difference Gel Electrophoresis

Urinary Proteome Analysis by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry with Magnetic Beads for Identifying the Pathologic Presentation of Clinical Early Iga Nephropathy

Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis

Preliminary Analysis on Urinary Proteomics of Children with Minimal Change Nephrotic Syndrome

Urinary proteomics for noninvasive monitoring of biomarkers of chronic mountain sickness in a young adult population using data-independent acquisition (DIA)-based mass spectrometry

Analysis of Differentially Expressed Proteome in Urinary Exosome from Non-small Cell Lung Cancer Patients

Profiling of Serum Bile Acids in A Healthy Chinese Population Using Uplc-Ms/Ms

Identification of urinary biomarkers for type 2 diabetes using bead-based proteomic approach.

Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease

Analysis of the differential urinary protein profile in IgA nephropathy patients of Uygur ethnicity

Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics

Exploration of potential biomarkers for early bladder cancer based on urine proteomics

Urinary Proteomic Characteristics of Hyperuricemia and Their Possible Links with the Occurrence of Its Concomitant Diseases

Analysis of Risk Factors Associated with Parkinson's Disease in Li Region in Hainan Area of China

Urine Proteome in Patients With Metabolic Associated Fatty Liver Disease

Geography and ethnicity related variation in the Chinese human milk serum proteome

Urinary metal and metalloid biomarker study of Henoch-Schonlein purpura nephritis using inductively coupled plasma orthogonal acceleration time-of-flight mass spectrometry